Quark Venture
34
22M
24
4.25
5
0.29
4
- Areas of investment
Summary
Quark Venture appeared to be the VC, which was created in 2015. The main department of described VC is located in the Vancouver. The company was established in North America in Canada.
The overall number of key employees were 3.
The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. This Quark Venture works on 17 percentage points less the average amount of lead investments comparing to the other organizations.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Quark Venture, startups are often financed by Yaletown Partners, Pontifax, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Pontifax, Yonghua Capital, Yaletown Partners. In the next rounds fund is usually obtained by GF Securities, Polaris Partners, Orient Life.
Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Among the various public portfolio startups of the fund, we may underline MSI Methylation Sciences, SQZ Biotech, Lyndra Therapeutics Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
Investments analytics
Analytics
- Total investments
- 34
- Lead investments
- 5
- Exits
- 4
- Rounds per year
- 4.25
- Follow on index
- 0.29
- Investments by industry
- Biotechnology (24)
- Health Care (17)
- Medical (12)
- Pharmaceutical (11)
- Therapeutics (9) Show 17 more
- Investments by region
-
- United States (17)
- Israel (6)
- Canada (10)
- France (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 7M
- Group Appearance index
- 0.88
- Avg. company exit year
- 1
- Avg. multiplicator
- 61.67
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| V-Wave | 16 Dec 2021 | Biotechnology, Health Care, Medical Device, Medical | Late Stage Venture | 98M | North District, Israel, Israel |
| Volastra Therapeutics | 11 Feb 2020 | Biotechnology, Medical | Seed | 12M | United States, New York, New York |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.